BIOBVNasdaq HelsinkiBiotechnologyIFRS · EUR

Biohit Oyj

Biohit Oyj is a Finnish biotechnology company that operates on a global scale, focusing on the development of diagnostic products and health-promoting supplements. Established in 1988, the company is headquartered in Helsinki, Finland, with subsidiaries in Italy and the United Kingdom. Biohit's mission, 'Innovating for Health,' drives its commitment to addressing global health challenges through innovative solutions. The company's shares are listed on the NASDAQ OMX Helsinki in the Small Cap Healthcare group.

Revenue15.7m EUR
+10.1 %y/y
Operating profit (EBIT)2.9m EUR
+14.4 %y/y
EBIT margin18.6%
+0.7 ppy/y
Net income2,568m EUR
+99,900.0 %y/y
Free cash flow-1.4m EUR
−832.8 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-505101520m EUR2020: 7.1 m EUR2020: EBIT -3.2 m EUR20202021: 9.4 m EUR2021: EBIT -1.5 m EUR20212022: 11 m EUR2022: EBIT 1.1 m EUR20222023: 13 m EUR2023: EBIT 1.8 m EUR20232024: 14 m EUR2024: EBIT 2.6 m EUR20242025: 16 m EUR2025: EBIT 2.9 m EUR2025162.9
RevenueOperating profit (EBIT)

Business

Share of revenue
Diagnostic Tests40 %

Includes tests for various health conditions, particularly gastrointestinal issues.

Acetaldehyde-binding Products25 %

Products designed to bind acetaldehyde, a harmful compound.

Monoclonal Antibodies15 %

Used in various diagnostic and therapeutic applications.

Licensing20 %

Licensing of Biohit's intellectual property to other manufacturers.

Customers

Biohit's customer base includes healthcare providers, diagnostic laboratories, and pharmaceutical companies. These customers utilize Biohit's products for diagnosing and managing gastrointestinal conditions, among others. The company's licensing agreements allow other manufacturers to produce and sell products based on Biohit's intellectual property. Additionally, Biohit's innovative solutions appeal to healthcare systems facing resource constraints and an aging population.

Healthcare Providers

Purchase diagnostic tests for patient care.

Diagnostic Laboratories

Use Biohit's tests for accurate diagnostics.

Pharmaceutical Companies

Acquire monoclonal antibodies for research and development.

Manufacturers

License Biohit's IP to produce and sell products.

Strategy

Biohit's strategic priorities focus on addressing global health challenges through innovation and collaboration. The company aims to combine profitable business with scientific advancement, particularly in gastrointestinal health. Biohit is committed to developing premium products and expanding its market presence through strategic partnerships. The company also emphasizes the importance of adapting to regulatory changes to ensure continued product sales.

Innovation in Gastrointestinal HealthMedium term

To address the increasing prevalence of digestive disorders.

Regulatory AdaptationShort term

To comply with new EU IVDR regulations.

Market ExpansionLong term

To increase global reach and sales.

Geography

Q4/2025

Biohit operates globally with a significant presence in Europe, Asia, and South America. The company's headquarters are in Helsinki, Finland, with subsidiaries in Italy and the UK. Biohit's products are sold in multiple regions, with Europe and Asia being key markets. The company participates in international health technology exhibitions to expand its market reach.

Asia46 %
Other Europe33 %
Other countries18 %
Americas2.4 %
Finland1.2 %

Share of the revenue the company reports by geography.

Risks

Biohit faces several risks, including regulatory compliance challenges and the need for successful product registrations. The company's reliance on key markets like China poses geopolitical risks. Additionally, Biohit's investment portfolio is exposed to market volatility and currency fluctuations. The nature of the biotechnology industry also presents inherent risks related to product development and market acceptance.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Geopolitical Exposure1Regulatory Compliance2Market Volatility3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Geopolitical ExposureImpact: CriticalLikelihood: Medium

    Significant sales in China.

  2. Regulatory ComplianceImpact: HighLikelihood: Medium

    Varied registration processes across markets.

  3. Market VolatilityImpact: MediumLikelihood: Low

    Investment portfolio exposed to market changes.

Accounting

Judgemental items
Revenue Recognition

Timing affects financial results.

Impact: high

Licensing Agreements

Separate performance obligations impact revenue.

Impact: medium

Lease Accounting

IFRS 16 affects asset and liability measurement.

Impact: medium

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026

Biohit Oyj (BIOBV) Revenue, Earnings & Financials 2025 – Clarifo